Navigation Links
Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinson's Disease on Their Largest Commercial Plan

BURLINGTON, Mass., Aug. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that up to 60 percent of surveyed U.S. managed care organization (MCO) pharmacy and medical directors expect to reimburse several late-stage emerging Parkinson's disease (PD) therapies on their largest risk-based commercial plan. Profiled in the report are four emerging agents that target primarily underserved populations, including IPX-066 (Impax Laboratories' Rytary), an extended-release reformulation of levodopa (multiple brands, generics), the mainstay of PD treatment, Acadia Pharmaceuticals' pimavanserin for PD-related psychotic symptoms, Novartis's mavoglurant (AFQ-056) for dyskinesias and Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma's MAO-B inhibitor safinamide.

The U.S. Physician and Payer Forum report entitled The Complex Parkinson's Disease Treatment Algorithm: U.S. Physician and Payer Perspectives on the Current and Future Landscape finds that formulary exclusion can be common for current PD brands, with at least one-third of MCO respondents indicating that their largest commercial plans and Medicare prescription drug plans exclude or block key brands from coverage. The most recent market entrant, UCB's dopamine agonist Neupro (rotigotine), is similarly covered, despite offering once-daily dosing and unique transdermal delivery. Nevertheless, when reimbursing key current brands, surveyed payers largely include such agents on tiers 2 and 3 (i.e. commonly preferred and non-preferred brands, respectively), and generally expect similar tier placement for the emerging agents profiled if priced at approximately $10 per day or higher.

The report also finds that surveyed neurologists estimate the eligible patient pool for emerging products queried to be no less than one quarter of their diagnosed PD patients, on average. Moreover, they anticipate that up to two-thirds of eligible patients would be treated with each product within one year of launch, with IPX-066 projected to capture the greatest patient share at approximately 25 percent of diagnosed PD patients if reimbursed on a preferred tier.

"Cost and reimbursement factors have a prominent role in determining the uptake of a PD therapy, but clinical considerations most influence prescribing decisions," said Decision Resources Senior Business Insights Analyst Nadja Rozovsky, Ph.D. "Despite the potential for certain constraints on reimbursement and finite patient eligibility, commercial opportunity remains for key late-stage investigational products in light of lingering unmet need."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort


SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Health-Conscious Women are Sixty Percent More Likely to Prefer Popular Brand-Name Drugs, Even if They Cost More
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
5. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
6. "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
7. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
8. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
9. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
10. Elekta Technology at Work in 100 Percent of Americas Top Cancer Hospitals
11. New Analysis Shows Illicit Drug Use May Vary by Payer Type: Detection Rates as High as 17 Percent
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
Breaking Medicine News(10 mins):